FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152493451> ?p ?o ?g. }

• W3152493451 endingPage "e1507" @default.
• W3152493451 startingPage "e1499" @default.
• W3152493451 abstract "Abstract Lessons Learned Disease control with signals of response were demonstrated, which should lead to future validating clinical trials using checkpoint inhibitors in this underserved rare malignancy population. Although the study of single types of rare cancers is practically challenging, clinical trial designs that aggregate such patients into cohorts treated similarly are feasible, even in the community setting. Background Patients with rare cancers are an underserved population with limited access to clinical trials aside from phase I trials in the refractory setting. Treatment of these patients is often based on collections of anecdotes and small denominator review articles. Despite broad evidence of efficacy of combined immune checkpoint blockade across multiple tumor types, patients with rare tumors have not been afforded the opportunity for these therapies. Methods A phase II, investigator-initiated, single institution trial using durvalumab (1,500 mg every [Q]4 weeks × 13) and tremelimumab (75 mg Q4 weeks × 7, then Q12 weeks × 2) is reported. The population included 50 patients with advanced rare solid tumors (incidence &lt;6/100,000 per year). The phase II dose and safety profile were defined in prior phase I trials. All patients had exhausted standard therapy options and all had received at least one prior line of systemic therapy (n = 49) unless a standard treatment option did not exist (n = 1). Results A complete response was demonstrated in one patient with anal cancer. Striking partial responses were seen in four patients. Prolonged disease stability was noted in 18 patients. Thirteen patients experienced disease progression. Patients were considered unevaluable if unable to initiate therapy (n = 6) or unable to complete two cycles of therapy (n = 8). In all cases, patients were unevaluable because of clinical deterioration. The toxicity profile paralleled prior published studies. Toxicities were manageable and without new signals. There were two events of grade 4 immune-mediated hepatitis and one death from pneumonitis. Conclusion This single-cohort basket trial demonstrated clinical activity from combined checkpoint blockade in 23 of the 36 evaluable patients. Patients with rare cancers, not eligible for immunotherapy via conventional clinical trial mechanisms, should be considered for this therapy through compassionate use, further clinical trials, and national registry programs." @default.
• W3152493451 created "2021-04-26" @default.
• W3152493451 creator A5006591586 @default.
• W3152493451 creator A5019666497 @default.
• W3152493451 creator A5020228359 @default.
• W3152493451 creator A5025528921 @default.
• W3152493451 creator A5037866301 @default.
• W3152493451 creator A5054365975 @default.
• W3152493451 creator A5067593030 @default.
• W3152493451 creator A5080693592 @default.
• W3152493451 date "2021-05-08" @default.
• W3152493451 modified "2023-10-16" @default.
• W3152493451 title "A Phase <scp>II</scp> Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers" @default.
• W3152493451 cites W2019607817 @default.
• W3152493451 cites W2066671159 @default.
• W3152493451 cites W2126438085 @default.
• W3152493451 cites W2143163879 @default.
• W3152493451 cites W2266707907 @default.
• W3152493451 cites W2590114264 @default.
• W3152493451 cites W2616456558 @default.
• W3152493451 cites W2620457065 @default.
• W3152493451 cites W3002973089 @default.
• W3152493451 cites W3006241692 @default.
• W3152493451 cites W3046384500 @default.
• W3152493451 doi "https://doi.org/10.1002/onco.13798" @default.
• W3152493451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8417875" @default.
• W3152493451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33893692" @default.
• W3152493451 hasPublicationYear "2021" @default.
• W3152493451 type Work @default.
• W3152493451 sameAs 3152493451 @default.
• W3152493451 citedByCount "7" @default.
• W3152493451 countsByYear W31524934512021 @default.
• W3152493451 countsByYear W31524934512022 @default.
• W3152493451 countsByYear W31524934512023 @default.
• W3152493451 crossrefType "journal-article" @default.
• W3152493451 hasAuthorship W3152493451A5006591586 @default.
• W3152493451 hasAuthorship W3152493451A5019666497 @default.
• W3152493451 hasAuthorship W3152493451A5020228359 @default.
• W3152493451 hasAuthorship W3152493451A5025528921 @default.
• W3152493451 hasAuthorship W3152493451A5037866301 @default.
• W3152493451 hasAuthorship W3152493451A5054365975 @default.
• W3152493451 hasAuthorship W3152493451A5067593030 @default.
• W3152493451 hasAuthorship W3152493451A5080693592 @default.
• W3152493451 hasBestOaLocation W31524934511 @default.
• W3152493451 hasConcept C121332964 @default.
• W3152493451 hasConcept C121608353 @default.
• W3152493451 hasConcept C126322002 @default.
• W3152493451 hasConcept C142424586 @default.
• W3152493451 hasConcept C143998085 @default.
• W3152493451 hasConcept C2777701055 @default.
• W3152493451 hasConcept C2777742743 @default.
• W3152493451 hasConcept C2778650287 @default.
• W3152493451 hasConcept C2779399171 @default.
• W3152493451 hasConcept C2779984678 @default.
• W3152493451 hasConcept C2780057760 @default.
• W3152493451 hasConcept C2781433595 @default.
• W3152493451 hasConcept C2908647359 @default.
• W3152493451 hasConcept C31760486 @default.
• W3152493451 hasConcept C535046627 @default.
• W3152493451 hasConcept C71924100 @default.
• W3152493451 hasConcept C87355193 @default.
• W3152493451 hasConcept C99454951 @default.
• W3152493451 hasConceptScore W3152493451C121332964 @default.
• W3152493451 hasConceptScore W3152493451C121608353 @default.
• W3152493451 hasConceptScore W3152493451C126322002 @default.
• W3152493451 hasConceptScore W3152493451C142424586 @default.
• W3152493451 hasConceptScore W3152493451C143998085 @default.
• W3152493451 hasConceptScore W3152493451C2777701055 @default.
• W3152493451 hasConceptScore W3152493451C2777742743 @default.
• W3152493451 hasConceptScore W3152493451C2778650287 @default.
• W3152493451 hasConceptScore W3152493451C2779399171 @default.
• W3152493451 hasConceptScore W3152493451C2779984678 @default.
• W3152493451 hasConceptScore W3152493451C2780057760 @default.
• W3152493451 hasConceptScore W3152493451C2781433595 @default.
• W3152493451 hasConceptScore W3152493451C2908647359 @default.
• W3152493451 hasConceptScore W3152493451C31760486 @default.
• W3152493451 hasConceptScore W3152493451C535046627 @default.
• W3152493451 hasConceptScore W3152493451C71924100 @default.
• W3152493451 hasConceptScore W3152493451C87355193 @default.
• W3152493451 hasConceptScore W3152493451C99454951 @default.
• W3152493451 hasIssue "9" @default.
• W3152493451 hasLocation W31524934511 @default.
• W3152493451 hasLocation W31524934512 @default.
• W3152493451 hasOpenAccess W3152493451 @default.
• W3152493451 hasPrimaryLocation W31524934511 @default.
• W3152493451 hasRelatedWork W2189031665 @default.
• W3152493451 hasRelatedWork W2738397398 @default.
• W3152493451 hasRelatedWork W2898433805 @default.
• W3152493451 hasRelatedWork W3049083268 @default.
• W3152493451 hasRelatedWork W3128798441 @default.
• W3152493451 hasRelatedWork W3152493451 @default.
• W3152493451 hasRelatedWork W3153820261 @default.
• W3152493451 hasRelatedWork W4295837292 @default.
• W3152493451 hasRelatedWork W4321441516 @default.
• W3152493451 hasRelatedWork W4367835718 @default.
• W3152493451 hasVolume "26" @default.
• W3152493451 isParatext "false" @default.
• W3152493451 isRetracted "false" @default.

• next